Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Enlicitide Decanoate in Pediatric Participants With Heterozygous Familial Hypercholesterolemia

NCT07058077 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT07058077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07058077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Enlicitide Decanoate in Pediatric Participants With Heterozygous Familial Hypercholesterolemia
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2/3
Overall status
Recruiting
Start date
August 21, 2025
Completion date
January 23, 2037
Enrollment
153 (estimated)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

heterozygous familial hypercholesterolemia (hefh)